Access Programs
214 programsBurundi Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program60d
Cabo Verde Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program45d
Cambodia Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program45d
Cameroon Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program30d
Central African Republic Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program60d
Chad Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program60d
Chile Named Patient Program
Framework: Health Code Article 100
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program30d
China Compassionate Use Program
Framework: Drug Administration Law 2019
Patient with serious or life-threatening condition, no registered alternative available
Compassionate Use60d
Colombia Named Patient Program
Framework: Decreto 677 de 1995
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program21d
Comoros Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program60d
Compassionate Use Program
Framework: EMA Article 83, FDA Expanded Access
Serious or life-threatening condition, no alternative treatment, benefit-risk assessment.
Compassionate Use30d
Congo (Democratic Republic) Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program60d
Congo Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program60d
Costa Rica Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program30d
Côte d'Ivoire Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program30d
Cuba Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program45d
Djibouti Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program60d
Dominica Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program45d
Dominican Republic Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program30d
Early Access Program
Framework: MHRA EAMS, ANSM ATU
Pre-approval drug with strong efficacy data in clinical trials.
Early Access90d
Ecuador Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program30d
Egypt Compassionate Use Program
Framework: Pharmacy Practice Law No. 127/1955
Patient with serious or life-threatening condition, no registered alternative available
Compassionate Use30d
El Salvador Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program30d
EMA Compassionate Use Programme
Framework: EU Regulation 726/2004 Article 83
Patient group with chronically or seriously debilitating disease or life-threatening condition; no authorized treatment available; patient cannot enter clinical trial; medicinal product subject to marketing authorization application or clinical trials
Compassionate Use60d
Equatorial Guinea Named Patient Program
Patient with serious or life-threatening condition, no registered alternative available
Named Patient Program45d